# A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS)

> **NCT04691141** · PHASE1,PHASE2 · TERMINATED · sponsor: **Shanghai Antengene Corporation Limited** · enrollment: 15 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** ATG-016

## Key facts

- **NCT ID:** NCT04691141
- **Lead sponsor:** Shanghai Antengene Corporation Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-23
- **Primary completion:** 2023-09-19
- **Final completion:** 2023-09-19
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** The study was stopped early because the sponsor decided to change the study-drug development strategy
- **Last updated:** 2024-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04691141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04691141, "A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04691141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*